Biomedicine

CLC number: Q819

Antitumor Response of Anti-B7-H3 CAR-T Cells with Humanized scFv in Solid Tumors

¹ School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, Jiangsu, China
² Zhangda Hospital, School of Medicine, Southeast University, Nanjing 210009, Jiangsu, China
³ Jiangsu Yinfeng Biological Technology Co. Ltd, Nanjing 210014, Jiangsu, China

^† To whom correspondence should be addressed. E-mail: zdxiao@seu.edu.cn;
shenyang0924@sina.cn

Received: 7 January 2022

Abstract

We prepared a humanized alternative B7-H3 CAR (B7-H3-haCAR-T) targeting B7-H3 which contained the humanized singl-chain varinlde fragment (scFv) from humanized 8H9 Monoclonal Antibody (hu8H9mAb). The antitumor effects of B7-H3-haCAR-T cells were evaluated in B7-H3 overexpressed tumor cells (in vitro) and B7-H3 xenograft models (in vivo). The specific tumour killing ability of B7-H3-haCAR-T in overexpressing B7-H3 tumour cells was verified by cytotoxicity and ELISA tests. In addition, B7-H3 haCAR-T cells were also noted to suppress the tumour growth remarkably well in the xenograft murine models, and the survival time in the haCAR-T cell treatment group was appreciably longer than that in the control group. The specific recognition and highly efficient tumoricidal behavior of B7-H3 haCAR-T provide a basis for future clinical studies with humanized scFv-transduced CAR-T cells targeting solid tumors.